Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) + pembrolizumab (pembro) + carboplatin (carbo) ± bevacizumab (bev) in ...

A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer. Background: The therapeutic benefit of pelvic lymph node dissection (PLND) ...

We read with interest the Article by Giacomo Montagna and colleagues1 evaluating oncological outcomes in patients with residual nodal micrometastatic disease (ypN1mi) following neoadjuvant systemic ...

Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...

For years, surgery for patients with stage III melanoma - melanoma that has spread to the lymph nodes - involved removing those lymph nodes along with the primary tumor. Known as completion lymph node ...

SAN ANTONIO -- Neoadjuvant chemotherapy that downstaged positive lymph nodes to negative led to a low rate of invasive breast cancer recurrence with either targeted axillary dissection (TAD) or ...

Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...

Extended dissection did not improve recurrence-free or overall survival, but it may have a bladder cancer-specific survival benefit possibly because it removes micrometastases. Extended lymph node ...

Patients with breast cancer may be able to avoid lymphedema, which can occur after surgery to remove lymph nodes in the ...

Ten-year findings suggest some patients may safely receive less treatment, potentially lowering side effects without raising ...